These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36726477)

  • 41. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
    Janto K; Prichard JR; Pusalavidyasagar S
    J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis.
    Xue T; Wu X; Li J; Chen S; Wang Z; Tan X; Wang Z; Zhang J
    Front Pharmacol; 2023; 14():1175372. PubMed ID: 37261282
    [No Abstract]   [Full Text] [Related]  

  • 43. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.
    Atkin T; Comai S; Gobbi G
    Pharmacol Rev; 2018 Apr; 70(2):197-245. PubMed ID: 29487083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Suvorexant: something new for sleep?
    Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
    Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
    Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia.
    Yoshikawa F; Shigiyama F; Ando Y; Miyagi M; Uchino H; Hirose T; Kumashiro N
    Diabetes Res Clin Pract; 2020 Nov; 169():108412. PubMed ID: 32911037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of suvorexant versus benzodiazepine receptor agonist sleep drugs in reducing the risk of hip fracture: Findings from a regional population-based cohort study.
    Yoshioka R; Yamamoto S; Nakatani E
    PLoS One; 2023; 18(4):e0284726. PubMed ID: 37093840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit.
    Azimaraghi O; Hammer M; Santer P; Platzbecker K; Althoff FC; Patrocinio M; Grabitz SD; Wongtangman K; Rumyantsev S; Xu X; Schaefer MS; Fuller PM; Subramaniam B; Eikermann M
    BMJ Open; 2020 Jul; 10(7):e038474. PubMed ID: 32690536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Sleep and its' disturbanses in chronic obstructive pulmonary disease].
    Palman AD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(4. Vyp. 2):113-118. PubMed ID: 30059060
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review.
    Adams AD; Pepin MJ; Brown JN
    J Crit Care; 2020 Oct; 59():1-5. PubMed ID: 32480359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New pharmacologic agents for insomnia and hypersomnia.
    Earl DC; Van Tyle KM
    Curr Opin Pulm Med; 2020 Nov; 26(6):629-633. PubMed ID: 32890017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Comprehensive Review of Lemborexant to Treat Insomnia.
    Fuller MC; Carlson SF; Grant C; Berry V; Ivancich M; Cornett EM; Kaye AM; Viswanath O; Urits I; Shekoohi S; Kaye AD
    Psychopharmacol Bull; 2024 Mar; 54(1):43-64. PubMed ID: 38449475
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
    Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
    Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians.
    Wilt TJ; MacDonald R; Brasure M; Olson CM; Carlyle M; Fuchs E; Khawaja IS; Diem S; Koffel E; Ouellette J; Butler M; Kane RL
    Ann Intern Med; 2016 Jul; 165(2):103-12. PubMed ID: 27136278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
    Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of suvorexant on sleep apnea in patients with heart failure: A protocol of crossover pilot trial.
    Shitara J; Kasai T; Akihiro S; Yatsu S; Matsumoto H; Suda S; Ogita M; Yanagisawa N; Fujibayashi K; Nojiri S; Nishizaki Y; Ono N; Suwa S; Daida H
    J Cardiol; 2019 Jul; 74(1):90-94. PubMed ID: 30737183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinct effects of orexin receptor antagonist and GABA
    Seol J; Fujii Y; Park I; Suzuki Y; Kawana F; Yajima K; Fukusumi S; Okura T; Satoh M; Tokuyama K; Kokubo T; Yanagisawa M
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24353-24358. PubMed ID: 31712421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.